ライフサイエンスコーパス: prophylaxis

1 t received 5-hour intravenous corticosteroid prophylaxis.

2 was significantly associated with atovaquone prophylaxis.

3 s received SRP and surgery, and HVs received prophylaxis.

4 ndard intravenous preoperative cephalosporin prophylaxis.

5 nst Aspergillus infections for treatment and prophylaxis.

6 for transmission reduction, and pre-exposure prophylaxis.

7 vices including antiretroviral treatment and prophylaxis.

8 atient received any posttransplantation GVHD prophylaxis.

9 amide-based graft-versus-host disease (GVHD) prophylaxis.

10 ealth care workers too late for postexposure prophylaxis.

11 , despite the availability of antiretroviral prophylaxis.

12 median, 55 days), all of whom received prior prophylaxis.

13 A for treatment of bleeding episodes or for prophylaxis.

14 fore and after initiation of IC moxifloxacin prophylaxis.

15 ipt of perinatal HIV testing, treatment, and prophylaxis.

16 ith SCID and designing the approach for GVHD prophylaxis.

17 -exposed children as opportunistic infection prophylaxis.

18 in 77% of cases, and all but 4 received GvHD prophylaxis.

19 us fumigatus are associated with caspofungin prophylaxis.

20 breast cancer, ductal carcinoma in situ, or prophylaxis.

21 e anti-HBs-negative should receive antiviral prophylaxis.

22 reduction strategies, including preexposure prophylaxis.

23 novel tools for treatment-as-prevention and prophylaxis.

24 tratification of recipients, monitoring, and prophylaxis.

25 HIV-negative persons receiving pre-exposure prophylaxis.

26 , possibly because frequent bleeders adopted prophylaxis.

27 y disease (CKD), with no available effective prophylaxis.

28 mal antibiotic choice, dosage, and length of prophylaxis.

29 and reduced HSV-2 acquisition as preexposure prophylaxis.

30 ed for primary prophylaxis and for secondary prophylaxis.

31 e option for surgeons electing IC antibiotic prophylaxis.

32 Six cases were receiving atovaquone as a prophylaxis.

33 an immunodeficiency virus (HIV) pre-exposure prophylaxis.

34 The majority of patients received mechanical prophylaxis.

35 ition to tacrolimus and methotrexate as GVHD prophylaxis.

36 al anti-infection immunity effect of TMP-SMX prophylaxis.

37 75% of children and youths <20 years were on prophylaxis.

38 lable evidence in administering CNS-directed prophylaxis.

39 une blistering diseases receiving no routine prophylaxis.

40 S >/= 3), those that received LMWH or UH VTE prophylaxis.

41 luate the safety of withholding stress ulcer prophylaxis.

42 robial agents for treatment and postexposure prophylaxis.

43 administered in conjunction with vancomycin prophylaxis.

44 cipants receiving FIX at study entry stopped prophylaxis.

45 s may warrant further study for pre-exposure prophylaxis.

46 idal anti-inflammatory drug (NSAID) bleeding prophylaxis.

47 .5% has been proposed as a cutoff to justify prophylaxis.

48 ecide on required antibiotic and antimycotic prophylaxis.

49 e of SSI (66/6,953, 0.95%) than single-agent prophylaxis (190/12,834, 1.48%; crude risk ratio [RR] 0.

50 oint bleeding decreased proportionately with prophylaxis (22%) and nonprophylaxis (23%), and target j

51 events were less common with anticoagulation prophylaxis (4/233, 2%) than without (9/66, 14%) (P<0.00

52 All patients were initially given rFIXFc prophylaxis (50-60 IU/kg) once per week with adjustments

53 Of 344 included patients, 173 received no prophylaxis, 69 received levofloxacin prophylaxis, and 1

54 rophylaxis was lower than that with standard prophylaxis (80 patients [8.9% vs. 108 [12.2%]; hazard r

55 (23%), and target joints decreased more with prophylaxis (80% vs 61%).

56 le 233 patients were implanted for secondary prophylaxis; 884 patients were randomized to ICD and 880

57 anced prophylaxis (906 patients) or standard prophylaxis (899 patients) and were followed for 48 week

58 ent randomization to receive either enhanced prophylaxis (906 patients) or standard prophylaxis (899

59 ived the standard preoperative cephalosporin prophylaxis, a postoperative 48-hour course of oral ceph

60 urrently recommended for variceal rebleeding prophylaxis, a recommendation that extends to all patien

61 hanced antimicrobial prophylaxis or standard prophylaxis, adjunctive raltegravir or no raltegravir, a

62 reaction rate of intravenous corticosteroid prophylaxis administered 5 hours before contrast materia

63 ew data indicate the importance of long-term prophylaxis after a first manic episode to lessen episod

64 Tac/Mtx) as graft-versus-host disease (GVHD) prophylaxis after matched-related allogeneic hematopoiet

65 ide (PTCy) can function as single-agent GVHD prophylaxis after myeloablative, HLA-matched related (MR

66 Cohorts B and C received dexamethasone prophylaxis against capillary leak syndrome (CLS).

67 tion (LT) centers administer long courses of prophylaxis against cytomegalovirus (CMV) without eviden

68 e of these countermeasures for post-exposure prophylaxis against Ebola virus infection.

69 lin (HBIG) has been an integral component of prophylaxis against hepatitis B virus (HBV) recurrence i

70 nt influenza virus vaccines are an effective prophylaxis against infection but are impacted by rapid

71 des delivered intranasally provide effective prophylaxis against MV infection.

72 Levofloxacin prophylaxis alone reduced these infections, but it also

73 orary control cohort receiving standard GVHD prophylaxis alone.

74 Levofloxacin prophylaxis also minimized the use of treatment antibiot

75 the greatest impact on uptake of antibiotic prophylaxis among patients with RHD in Uganda.

76 ts; 462 (12.8%) were prescribed for surgical prophylaxis and 2997 (83.0%) were prescribed for treatme

77 regulatory approval status of the drugs for prophylaxis and for acute treatment is different in each

78 n the groups of patients treated for primary prophylaxis and for secondary prophylaxis.

79 ients receiving concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with the first cou

80 ic classes used in graft-versus-host disease prophylaxis and in refractory graft-versus-host disease

81 A perspective on relevant topics in the prophylaxis and management of endophthalmitis.

82 definite statement about postoperative UDCA prophylaxis and most bariatric centers do not prescribe

83 allogeneic HSCT model for evaluation of GvHD prophylaxis and next-generation HSCT-mediated therapies

84 o association between receipt of combination prophylaxis and SSI was found for the other types of sur

85 ccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost ant

86 f implementing CCDSSs on the ordering of VTE prophylaxis and the rates of VTE.

87 evaluated whether MEDI8852 was effective for prophylaxis and therapy against representative group I (

88 e of a promising role for resveratrol in the prophylaxis and therapy of AD.

89 Prophylaxis and treatment guidelines for infective endoc

90 rugs with a well-established role in primary prophylaxis and treatment of CMV disease.

91 MEDI8852 was effective for prophylaxis and treatment of H7N9 and H5N1 infection in

92 d identify patients who may benefit from HBV prophylaxis and treatment.

93 uld be preferentially targeted for secondary prophylaxis and/or regular medical follow-up.

94 s of age who were treatment naive (excluding prophylaxis) and in whom an HIV PCR test was indicated w

95 ved no prophylaxis, 69 received levofloxacin prophylaxis, and 102 received other prophylaxis regimens

96 sal infection with H5N1 and H7N9 viruses for prophylaxis, and 24, 48, and 72 hours post-infection for

97 hematological malignancies without antiviral prophylaxis, anti-HBs positivity is associated with a de

98 at occur during posaconazole or voriconazole prophylaxis are rare complications for which epidemiolog

99 nts, and the effect of hospitalization-based prophylaxis are uncertain.

100 lethal opportunistic infection that primary prophylaxis can help prevent.

101 ed immunosuppression, enhanced antimicrobial prophylaxis combined with ART resulted in reduced rates

102 s 0.07% (75/104 894) without IC moxifloxacin prophylaxis, compared with 0.01% (11/89 358) with moxifl

103 0.07% (135/192 149) without IC moxifloxacin prophylaxis, compared with 0.02% (52/222 508) with moxif

104 V prevention services, including preexposure prophylaxis, compared with those who underwent universal

105 pective, multicenter study with uniform GVHD prophylaxis, conditioning regimen, and donor source, we

106 vention, including provision of pre-exposure prophylaxis, condom distribution, and male circumcision,

107 In future outbreaks, post-exposure prophylaxis could play an important part in reducing com

108 For acute infections, such as cholera, phage prophylaxis could provide a strategy to limit the impact

109 Despite CMV prophylaxis, D+R- KTRs are at greatest risk of CMV disea

110 as in patients with primary versus secondary prophylaxis defibrillator indications.

111 ents (24%) who received secondary octreotide prophylaxis developed another GI bleed, whereas 39 (76%)

112 s the largest study to date of antibacterial prophylaxis during induction therapy for pediatric ALL a

113 phylaxis, levofloxacin prophylaxis, or other prophylaxis during induction therapy on the total XVI st

114 Although intrapartum antibiotic prophylaxis during labor and delivery has decreased the

115 alaria parasites and speculated that TMP-SMX prophylaxis during repeated malaria exposures would indu

116 Prophylaxis failure, which caused delayed clinical prese

117 iclovir prophylaxis, PET did not differ from prophylaxis for any of the selected outcomes, but was ra

118 initiation of intracameral (IC) moxifloxacin prophylaxis for both phacoemulsification and sutureless,

119 the data supporting perioperative antibiotic prophylaxis for clean-contaminated surgeries, which sugg

120 Routine Pneumocystis prophylaxis for patients with autoimmune blistering dise

121 fovir disoproxil fumarate-based pre-exposure prophylaxis for the prevention of HIV infection.

122 s do not adequately stratify risk or provide prophylaxis for venous thromboembolism (VTE) among surgi

123 rease in the rate of appropriate ordering of prophylaxis for VTE (odds ratio, 2.35; 95% CI, 1.78-3.10

124 rgical patients who were prescribed adequate prophylaxis for VTE and correlates with a reduction in V

125 Rates of prophylaxis for VTE and VTE events.

126 s increased in the combination antimicrobial prophylaxis group (2,971/12,508 [23.8%] receiving combin

127 This effect was not seen in the secondary prophylaxis group (hazard ratio, 1.14; 95% confidence in

128 s and grade 4 adverse events in the enhanced-prophylaxis group (P=0.08 and P=0.09, respectively).

129 Patients in the enhanced-prophylaxis group had significantly lower rates of tuber

130 In the primary prophylaxis group, CRT-D significantly reduced incidence

131 Patients receiving prophylaxis had longer duration of neutropenia.

132 The type of prophylaxis had no effect on the need for unplanned retu

133 Anecdotal use of topical steroid oral prophylaxis has been reported in patients with breast ca

134 (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis has revolutionized haploidentical hematopoie

135 timing of surgery or the role of antibiotic prophylaxis have not been resolved.

136 ries with coverage of intrapartum antibiotic prophylaxis (IAP), used to reduce the incidence of EOGBS

137 spite declines due to intrapartum antibiotic prophylaxis (IAP).

138 on of subclinical disease and how antifungal prophylaxis impacts assay performance.

139 e development of antibodies for treatment or prophylaxis.IMPORTANCE In recent years, isolation of new

140 or to that of antiplatelet agents for stroke prophylaxis in AF, the optimal antithrombotic treatment

141 of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT.

142 As for secondary prophylaxis in children with established AD, this can be

143 rovisional guidance for use of post-exposure prophylaxis in Ebola virus disease and identify the prio

144 ter systematic trimethoprim-sulfamethoxazole prophylaxis in exposed patients.

145 determining the optimum duration of TMP-SMX prophylaxis in HIV-infected or HIV-exposed children must

146 The indication for prophylaxis in immunocompromised patients without HIV is

147 rials testing AzaC as a novel method of GvHD prophylaxis in man.

148 nsiderations, preventive strategies (such as prophylaxis in MDR and XDR contacts), palliative and pat

149 pre-F and post-F proteins, is restricted to prophylaxis in neonates at high risk of severe RSV disea

150 eparin (UH) for venous thromboembolism (VTE) prophylaxis in patients with severe traumatic brain inju

151 uptake of first-line Pneumocystis pneumonia prophylaxis in renal transplant recipients.

152 LMWH prophylaxis in severe TBI is associated with better surv

153 ction assessment and rechallenge to optimize prophylaxis in this patient cohort.

154 (VCF) placement for pulmonary embolism (PE) prophylaxis in trauma is controversial.

155 t LMWH may be more effective than UH for VTE prophylaxis in trauma patients.

156 rate-lowering therapy, including concomitant prophylaxis, in patients with recurrent gout attacks.

157 Risks of routine prophylaxis include hyperkalemia, hypoglycemia, photosen

158 Empiric antimycotic prophylaxis initiated at the time of positive culture re

159 sed bleeding at any age (P < .001), but only prophylaxis initiation prior to age 4 years and nonobesi

160 bolic complications, regardless of timing of prophylaxis initiation.

161 ld where low-molecular-weight heparin (LMWH) prophylaxis is clearly indicated or below a threshold wh

162 imal regimen for perioperative antimicrobial prophylaxis is controversial.

163 In addition, prophylaxis is not without risk of treatment-related com

164 to specific guidelines, nucleoside analogue prophylaxis is recommended in anti-HBc-positive liver al

165 Long-term antiviral prophylaxis is required to prevent hepatitis B recurrenc

166 Intrapartum antibiotic prophylaxis is the current mainstay of prevention, reduc

167 propofol was coadministered with vancomycin prophylaxis, it dramatically increased kidney abscess fo

168 eastfeeding as well as infant antiretroviral prophylaxis lead to high rates of pretreatment drug resi

169 related outcomes in patients who received no prophylaxis, levofloxacin prophylaxis, or other prophyla

170 disease (with/without intrapartum antibiotic prophylaxis), maternal GBS disease, neonatal/infant GBS

171 status suggests that MRSA-screening-directed prophylaxis may optimize benefits while minimizing harms

172 After enhancing tumour lysis syndrome prophylaxis measures and commencing venetoclax at 20 mg,

173 Prophylaxis most frequently involves trimethoprim-sulfam

174 that would be expected to provide effective prophylaxis of attacks.

175 nts with and without fluconazole for primary prophylaxis of cryptococcosis.

176 recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema.

177 this effect may have clinical utility in the prophylaxis of inflammatory atherosclerotic disease.

178 lloblastoma is secondary to the treatment or prophylaxis of leptomeningeal metastases, and the cause

179 nvestigate further the use of DSM265 for the prophylaxis of malaria.

180 rial that investigated dexamethasone for the prophylaxis of pain flare after radiotherapy, patients w

181 A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolon

182 Anti-GvHD prophylaxis of tacrolimus, post-transplant cyclophospham

183 ens Schou pioneered the study of lithium for prophylaxis of the recurrent mood disorder and encourage

184 CQ could be considered for the treatment and prophylaxis of ZIKV.

185 frequency to increase compliance, promoting prophylaxis, offering alternatives to inhibitor patients

186 come measure was the impact of postoperative prophylaxis on donor tissue-associated infections.

187 of a single dose of preoperative antibiotic prophylaxis on the incidence of SSIs following removal o

188 initively determine the impact of penicillin prophylaxis on the trajectory of latent RHD.

189 domization to receive enhanced antimicrobial prophylaxis or standard prophylaxis, adjunctive raltegra

190 No approved prophylaxis or therapy exists for these toxicities, in p

191 alone or with oseltamivir, shows promise for prophylaxis or therapy of group I and II IAVs with pande

192 ing all 3 recommended arms of antiretroviral prophylaxis or treatment (prenatal, intrapartum, and pos

193 (40.3%) (2010-2013) receiving antiretroviral prophylaxis or treatment during pregnancy.

194 ts for prebiotic and probiotic strategies as prophylaxis or treatment of GVHD.

195 ne use of cytomegalovirus immunoglobulin for prophylaxis or treatment of infected mothers.

196 l host mechanisms that can be used safely as prophylaxis or treatment to effectively ameliorate disea

197 ) may be a viable alternative for short-term prophylaxis or treatment.

198 10, the proportion of patients receiving VTE prophylaxis or with an indication that prophylaxis was u

199 ts who received no prophylaxis, levofloxacin prophylaxis, or other prophylaxis during induction thera

200 y consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic intensification, choleste

201 ite and test operator (P < .05), preexposure prophylaxis (P = .01), low plasma viral load (P < .02),

202 Rabies virus (RABV) postexposure prophylaxis (PEP) requires rapid vaccine-induced humoral

203 itis B virus exposures includes postexposure prophylaxis (PEP) when necessary; however, PEP is not re

204 are routinely used for measles post-exposure prophylaxis (PEP).

205 documented either at baseline or during the prophylaxis period, of which 83% were non-immune-mediate

206 cal cohort of children receiving ganciclovir prophylaxis, PET did not differ from prophylaxis for any

207 rozoites (PfSPZ Challenge) under chloroquine prophylaxis (PfSPZ-CVac), and were protected against con

208 duced-intensity allo-HSCT with standard GVHD prophylaxis plus maraviroc to a contemporary control coh

209 gitudinal analysis of individuals over time, prophylaxis predicted decreased bleeding at any age (P <

210 us non-daily dosing of oral HIV pre-exposure prophylaxis (PrEP) among women are unknown.

211 required to design delivery of pre-exposure prophylaxis (PrEP) and early antiretroviral treatment (A

212 that taking tenofovir daily as pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection

213 tify the circumstances in which pre-exposure prophylaxis (PrEP) could be used in Nairobi, Kenya.

214 nkage to addiction treatment or pre-exposure prophylaxis (PrEP) for HIV prevention through syringe se

215 Pre-exposure prophylaxis (PrEP) has been shown to be highly effective

216 of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in human immunodeficiency virus (HIV)

217 key population for implementing preexposure prophylaxis (PrEP) interventions worldwide, yet tenofovi

218 and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effective strategy to prevent a

219 Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) is high efficacious for HIV preventio

220 Preexposure prophylaxis (PrEP) is highly effective for preventing hu

221 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART

222 The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depe

223 omen who would most benefit from preexposure prophylaxis (PrEP) while minimizing unnecessary PrEP exp

224 Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir diso

225 er perspectives on their use as pre-exposure prophylaxis (PrEP), potential benefits beyond sterilizin

226 nt (Test & Treat), and oral HIV pre-exposure prophylaxis (PrEP).

227 MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP).

228 Prophylaxis prevented febrile neutropenia and systemic i

229 19 patients receiving Pneumocystis pneumonia prophylaxis prior to and after protocol implementation.

230 role for booster vaccinations, and antiviral prophylaxis prior to chemotherapy in this patient popula

231 Preexposure prophylaxis programs involve frequent human immunodefici

232 Prophylaxis reduced the odds of febrile neutropenia, lik

233 Routine IC moxifloxacin prophylaxis reduced the overall endophthalmitis rate by

234 Co-trimoxazole prophylaxis reduces mortality among HIV-infected childre

235 To determine whether ganciclovir prophylaxis reduces plasma interleukin 6 (IL-6) levels i

236 strated that adding olanzapine to antiemetic prophylaxis reduces the likelihood of nausea among adult

237 manual review of perioperative antimicrobial prophylaxis regimen and manual review for the 30-day inc

238 iretroviral treatment (ART) and pre-exposure prophylaxis regimens.

239 floxacin prophylaxis, and 102 received other prophylaxis regimens.

240 es, administration of surgical antimicrobial prophylaxis (SAP) for the prevention of surgical site in

241 n cesarean section procedures, antimicrobial prophylaxis should be administered before skin incision.

242 Antimicrobial prophylaxis should be administered only when indicated b

243 k is above a threshold where postpartum LMWH prophylaxis should be considered (4.4%; 95% CI, 1.2-9.5)

244 strength evidence indicates that duration of prophylaxis should be longer than 8 weeks.

245 r eyes complicated by PCR, and IC antibiotic prophylaxis should be strongly considered for this high-

246 that risk, including altering the antibiotic prophylaxis, should be investigated and implemented.

247 s who developed acute GVHD despite maraviroc prophylaxis showed increased T-cell activation, naive T-

248 study was to examine the effect of secondary prophylaxis (SP) on the risk of relapse in SOTRs followi

249 ariate analysis donor type (mother) and GVHD prophylaxis (T-cell depletion) were also significant pre

250 Without diarrhoea prophylaxis, the most common grade 3-4 adverse events in

251 lving 1,672 patients not receiving antiviral prophylaxis, the reactivation risk was 14% (95% confiden

252 properties of bacteriophages as a potential prophylaxis therapy for cholera, a severely dehydrating

253 in published studies on variceal rebleeding prophylaxis, there is a lack of information regarding re

254 nical trial of trimethoprim-sulfamethoxazole prophylaxis, there was no evidence that prolonged exposu

255 After professional prophylaxis, they were randomized into two groups receiv

256 h the introduction of intrapartum antibiotic prophylaxis, this pathogen remains a leading cause of ne

257 rget (longer duration) primary and secondary prophylaxis to high-risk individuals who would benefit m

258 HD progression and the ability of penicillin prophylaxis to improve outcome.

259 ease, who require antibiotic and antimycotic prophylaxis to prevent life-threatening bacterial and fu

260 ticipating in a clinical trial of antibiotic prophylaxis to prevent recurrent urinary tract infection

261 interventional assessment and antimicrobial prophylaxis to surgery including endoscopic injection of

262 ts enrolled in the Botswana TDF/FTC Oral HIV Prophylaxis Trial, the Bangkok Tenofovir Study, and the

263 for diagnostic testing and interventional HO prophylaxis trials.

264 se of albendazole, as compared with standard prophylaxis (trimethoprim-sulfamethoxazole alone).

265 lation (P < .001) in parallel with increased prophylaxis usage, possibly because frequent bleeders ad

266 ion surveillance registry assessed trends in prophylaxis use and its impact on key indicators of arth

267 During this time, prophylaxis use increased from 31% to 59% overall, and b

268 or guidelines for US women's HIV preexposure prophylaxis use.

269 /6,607 (0.9%) patients receiving combination prophylaxis versus 146/10,215 (1.4%) patients who receiv

270 346 (2.3%) patients who received combination prophylaxis versus 4/100 (4.0%) patients who received va

271 At quarterly maintenance or prophylaxis visits during the subsequent year, therapeut

272 sk stratification and assistance in ordering prophylaxis vs routine care without decision support wer

273 through reaction rate for 5-hour intravenous prophylaxis was 2.5% (five of 202 patients; 95% confiden

274 Among cardiac surgery patients, combination prophylaxis was associated with a lower incidence of SSI

275 In our study, combination prophylaxis was associated with both benefits (reduction

276 beneficial effect of intraductal antibiotic prophylaxis was even more evident (OR = 0.153; 95% CI: 0

277 with TE events were excluded and enoxaparin prophylaxis was initiated.

278 entified after trimethoprim-sulfamethoxazole prophylaxis was introduced in the entire cohort.

279 at 24 weeks, the rate of death with enhanced prophylaxis was lower than that with standard prophylaxi

280 Penicillin prophylaxis was prescribed in 49.3% with overall adheren

281 g VTE prophylaxis or with an indication that prophylaxis was unnecessary increased from approximately

282 durations of hospitalization and in-hospital prophylaxis were 3 days and 70 hours, respectively.

283 Joint, total, and target joint bleeding on prophylaxis were 33%, 41%, and 27%, respectively, compar

284 ve for HBsAg who were not receiving anti-HBV prophylaxis were enrolled.

285 le dose escalation, combination therapy, and prophylaxis were explored as strategies to overcome resi

286 ort on the effects of enhanced antimicrobial prophylaxis, which consisted of continuous trimethoprim-

287 m(2)) and intrathecal central nervous system prophylaxis while omitting maintenance therapy.

288 se, 1531 patients were implanted for primary prophylaxis, while 233 patients were implanted for secon

289 Use of combination prophylaxis with a beta-lactam plus vancomycin is increa

290 High-strength evidence shows that prophylaxis with daily colchicine or NSAIDs reduces the

291 with DSAs at transplant receiving rejection prophylaxis with eculizumab or standard of care (plasma

292 is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing ind

293 SUMMARY BACKGROUND DATA: Pharmacological VTE prophylaxis with LMWH or UH is the current standard of c

294 The results of our trials showed that prophylaxis with low-molecular-weight heparin for the 8

295 ssist device patients who received secondary prophylaxis with octreotide after their index GI bleed f

296 entricular assist device receiving secondary prophylaxis with octreotide had a significantly lower GI

297 INTERPRETATION: Prophylaxis with recombinant human C1 esterase inhibitor

298 Patients received GVHD prophylaxis with tacrolimus and methotrexate.

299 tial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted

300 head, thorax, and abdomen AIS, and timing of prophylaxis (within 48 hours, 49-72 hours, and >72 hours